Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Levetiracetam + lorazepam is a combination of two pharmaceutical drugs used primarily in the management of seizures, including status epilepticus. Levetiracetam is an anticonvulsant that acts mainly by binding to synaptic vesicle glycoprotein 2A (SV2A), modulating neurotransmitter release and stabilizing neuronal activity. Lorazepam is a benzodiazepine that enhances the inhibitory effect of gamma-aminobutyric acid (GABA) at GABA-A receptor, increasing chloride ion influx and hyperpolarizing neurons to reduce excitability. Both drugs are approved for seizure control; their combination may be used when rapid seizure cessation is required or when monotherapy fails[1][5][8]. Levetiracetam was developed as an antiepileptic agent, while lorazepam was developed for anxiety and acute seizure management.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on levetiracetam + lorazepam.